SOM Biotech attended the World Orphan Drug Congress USA 2017 (WODC) hold in Washington, USA on April 19th-21st. More than 1,000 global attendees did not want to miss the opportunity to discuss the latest trends on Orphan Drugs, a $140Billion dollar market.
Topics like pricing, reimbursement, M&A, commercialization, FDA’s considerations, scientific innovation, regional market analysis and funding strategies were covered among others. Additionally, a company pitching section was included were SOM Biotech’s CEO, Raúl Insa, presented the company under the watchful eye of investors, big pharma, patient foundations and other biotech companies. Dr. Insa stated the importance of drug repurposing in CNS indications, a market which sales are estimated to be $18.9Billion by 2019.
SOM Biotech Executive team at the WODC. From left to right Raúl Insa, CEO, Elena Díez, CPO, Raj Airey, CSO.